US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Adlai Nortye Ltd.

0.1835

0.0000

Volume:- -

Turnover:- -

Market Cap:12.58M

PE:1.53

High:0.1835

Open:0.1835

Low:0.1835

Close:0.1835

52wk High:0.1835

52wk Low:0.1835

Shares:68.57M

Float Shares:3.00M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.1200

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Analysts’ Opinions Are Mixed on These Healthcare Stocks: US Physical Therapy (USPH) and Adlai Nortye Ltd. Sponsored ADR (ANL)

Adlai Nortye H1 EPS $(0.04) Up From $(0.19) YoY, Sales $13.056M

Benzinga Earnings

Earnings Flash (ANL) Adlai Nortye Posts H1 Revenue $13.1M

MT Newswires Live

Adlai Nortye Initiated at Buy as First-in-Class RASiCA ADC Enters Clinic; $20 Price Target Reiterated

Adlai Nortye Receives Ethics Approval to Begin Phase 1 Trial of Cancer Drug AN4035

MT Newswires Live

Adlai Nortye Initiated With Buy on Differentiated RAS-Targeting Pipeline, ADC Strategy and Solid Cash Runway

Alnylam Expands Into Obesity With New Phase 1 Trial for ALN-6222

Adlai Nortye Ltd. Sponsored ADR (ANL) Receives a Buy from Cantor Fitzgerald

Adlai Nortye: Buy Rating Reaffirmed as Dual-Arm AN9025 Strategy Advances; $20 Price Target Maintained

Adlai Nortye Doses First US Patient in Weekly Arm of Phase 1 AN9025 Trial

MT Newswires Live

Adlai Nortye doses first patient in AN9025 trial

Press Release: Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists

Adlai Nortye Initiated at Overweight by Cantor Fitzgerald

Cantor Fitzgerald Initiates Adlai Nortye at Overweight

MT Newswires Live

Adlai Nortye initiated with an Overweight at Cantor Fitzgerald

Analysts Offer Insights on Healthcare Companies: MetaVia (MTVA) and Adlai Nortye Ltd. Sponsored ADR (ANL)

Adlai Nortye initiated with an Outperform at Oppenheimer

Oppenheimer Initiates Adlai Nortye With Outperform Rating, $32 Price Target

MT Newswires Live

Adlai Nortye Initiated at Buy by Jones Trading

Alnylam Steps Into Obesity Drug Race With New ALN-2232 Trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/ALN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALN\",,,,,undefined,":{"symbol":"ALN","market":"US","secType":"STK","nameCN":"Adlai Nortye Ltd.","latestPrice":0.1835,"timestamp":1787342400000,"preClose":0.1835,"halted":9,"volume":0,"delay":0,"changeRate":0,"floatShares":3000000,"shares":68570000,"eps":0.12,"marketStatus":"Market Closed","change":0,"latestTime":"08-21 16:00:00 EDT","open":0.1835,"high":0.1835,"low":0.1835,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.12,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1692331200000,"exchange":"NASDAQ","adjPreClose":0.1835,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALN\",,,,,undefined,":{"symbol":"ALN","floatShares":3000000,"roa":"--","roe":"--","lyrEps":0,"shares":68570000,"dividePrice":0,"high":0.1835,"amplitude":0,"preClose":0.1835,"low":0.1835,"week52Low":0.1835,"pbRate":"--","week52High":0.1835,"institutionHeld":0,"latestPrice":0.1835,"eps":0.12,"divideRate":0,"volume":0,"delay":0,"ttmEps":0.12,"open":0.1835},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALN\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659121302","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: US Physical Therapy (USPH) and Adlai Nortye Ltd. Sponsored ADR (ANL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659121302","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659121302?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:40","pubTimestamp":1786740009,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on US Physical Therapy (USPH) and Adlai Nortye Ltd. Sponsored ADR (A...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-us-physical-therapy-usph-and-adlai-nortye-ltd-sponsored-adr-anl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-us-physical-therapy-usph-and-adlai-nortye-ltd-sponsored-adr-anl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","AADR","BK4588","ANL","HCSG","BK4139","USPH","XLV","BK4581","APIE","BK4585","LU2133065610.SGD","DIVL","IE00BZ199S13.USD","LU0029874061.USD","LABU","SAPH","XBI","CVY","DINT","BK4137","ALN","ARMH","LU0012050646.USD","LU0106261612.USD","BK4185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659459061","title":"Adlai Nortye H1 EPS $(0.04) Up From $(0.19) YoY, Sales $13.056M","url":"https://stock-news.laohu8.com/highlight/detail?id=2659459061","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659459061?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:22","pubTimestamp":1786706547,"startTime":"0","endTime":"0","summary":"Adlai Nortye (NASDAQ:ANL) reported quarterly losses of $(0.04) per share. This is a 78.95 percent increase over losses of $(0.19) per share from the same period last year.  The company reported $13.056 million in sales","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61204389/adlai-nortye-h1-eps-0-04-0-19-yoy-sales-13-056m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659414301","title":"Earnings Flash (ANL) Adlai Nortye Posts H1 Revenue $13.1M","url":"https://stock-news.laohu8.com/highlight/detail?id=2659414301","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659414301?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:05","pubTimestamp":1786705552,"startTime":"0","endTime":"0","summary":"Earnings Flash (ANL) Adlai Nortye Posts H1 Revenue $13.1M","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALN","ANL.AU","ANL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656303170","title":"Adlai Nortye Initiated at Buy as First-in-Class RASiCA ADC Enters Clinic; $20 Price Target Reiterated","url":"https://stock-news.laohu8.com/highlight/detail?id=2656303170","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656303170?lang=en_us&edition=fundamental","pubTime":"2026-08-04 00:55","pubTimestamp":1785776118,"startTime":"0","endTime":"0","summary":"Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Adlai Nortye Ltd. Sponsored ADR. The associated price target remain...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/adlai-nortye-initiated-at-buy-as-first-in-class-rasica-adc-enters-clinic-20-price-target-reiterated-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/adlai-nortye-initiated-at-buy-as-first-in-class-rasica-adc-enters-clinic-20-price-target-reiterated-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALN","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656760873","title":"Adlai Nortye Receives Ethics Approval to Begin Phase 1 Trial of Cancer Drug AN4035","url":"https://stock-news.laohu8.com/highlight/detail?id=2656760873","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656760873?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:11","pubTimestamp":1785759089,"startTime":"0","endTime":"0","summary":"Adlai Nortye  said it has submitted a clinical trial notification to Australia's Therapeutic Goods Administration and received approval from the Human Research Ethics Committee to begin a phase 1 trial of AN4035.The global trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of AN4035, both as a monotherapy and in combination with cetuximab, in patients with CEACAM5-enriched, RAS-addicted solid tumors.AN4035 is a CEACAM5-targeting antibody-drug conjugate built around a pan-RAS inhibitor payload.The company expects to begin dosing patients in the second half of the year.Adlai Nortye also said it is filing investigational new drug applications for AN4035 with the US Food and Drug Administration and China's National Medical Products Administration.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2298322129.HKD","LU2133065610.SGD","IE00BZ199S13.USD","BK4588","LU1983260115.SGD","ON","ANL","BK4139","BK4585","LU1548497426.USD","BK4605","LU1978683503.SGD","IE00BFMHRM44.USD","BK7104","LU1861214812.USD","IE00BD6J9T35.USD","ALN","LU1854104046.USD","BK4141","LU1854103824.USD","LU2357305700.SGD","LU1861219969.SGD","LU1720051017.SGD","LU1861215975.USD","LU0348723411.USD","ANL.AU","LU2360107325.USD","LU0124384867.USD","BK4512","LU1861220033.SGD","LU0724618433.USD","LU1720051108.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654049878","title":"Adlai Nortye Initiated With Buy on Differentiated RAS-Targeting Pipeline, ADC Strategy and Solid Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2654049878","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654049878?lang=en_us&edition=fundamental","pubTime":"2026-07-27 22:55","pubTimestamp":1785164125,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Boris Peaker has maintained their bullish stance on ANL stock, giving a Buy rating on July 16. Boris Peaker has given his Buy ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/adlai-nortye-initiated-with-buy-on-differentiated-ras-targeting-pipeline-adc-strategy-and-solid-cash-runway-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/adlai-nortye-initiated-with-buy-on-differentiated-ras-targeting-pipeline-adc-strategy-and-solid-cash-runway-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADC","ALN","BK4139","BK4080","IE00BZ199S13.USD","NETL","LU2133065610.SGD","BK4231","ANL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654250036","title":"Alnylam Expands Into Obesity With New Phase 1 Trial for ALN-6222","url":"https://stock-news.laohu8.com/highlight/detail?id=2654250036","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654250036?lang=en_us&edition=fundamental","pubTime":"2026-07-25 00:33","pubTimestamp":1784910836,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals ($ALNY) announced an update on their ongoing clinical study. The Phase 1 study titled “A Phase 1, Randomized, Double-blind,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alnylam-expands-into-obesity-with-new-phase-1-trial-for-aln-6222?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alnylam-expands-into-obesity-with-new-phase-1-trial-for-aln-6222?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652918902","title":"Adlai Nortye Ltd. Sponsored ADR (ANL) Receives a Buy from Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2652918902","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652918902?lang=en_us&edition=fundamental","pubTime":"2026-07-20 17:06","pubTimestamp":1784538376,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Li Watsek maintained a Buy rating on Adlai Nortye Ltd. Sponsored ADR on July 16. The company’s shares closed last Friday ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/adlai-nortye-ltd-sponsored-adr-anl-receives-a-buy-from-cantor-fitzgerald-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/adlai-nortye-ltd-sponsored-adr-anl-receives-a-buy-from-cantor-fitzgerald-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALN","DINT","IE00BZ199S13.USD","BK4139","APIE","DIVL","LU2133065610.SGD","CVY","AADR","ANL","SAPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652266114","title":"Adlai Nortye: Buy Rating Reaffirmed as Dual-Arm AN9025 Strategy Advances; $20 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2652266114","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652266114?lang=en_us&edition=fundamental","pubTime":"2026-07-17 00:45","pubTimestamp":1784220325,"startTime":"0","endTime":"0","summary":"In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Adlai Nortye Ltd. Sponsored ADR, with a price target o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/adlai-nortye-buy-rating-reaffirmed-as-dual-arm-an9025-strategy-advances-20-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/adlai-nortye-buy-rating-reaffirmed-as-dual-arm-an9025-strategy-advances-20-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651449998","title":"Adlai Nortye Doses First US Patient in Weekly Arm of Phase 1 AN9025 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651449998","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651449998?lang=en_us&edition=fundamental","pubTime":"2026-07-16 19:37","pubTimestamp":1784201836,"startTime":"0","endTime":"0","summary":"Adlai Nortye  said Thursday it has dosed the first patient in the US in the intermittent weekly dosing arm of its phase 1 trial evaluating AN9025 in patients with advanced or metastatic solid tumors harboring RAS mutations.The company said that intermittent dosing offers a differentiated approach and may widen the therapeutic window based on preclinical data.Adlai said it plans to share initial phase 1 dose escalation data in the first half of next year from the continuous once-daily arm of the study, with a potential early look at the once-weekly arm.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ANL.AU","LU2133065610.SGD","BK7104","ALN","ANL","BK4139","IE00BZ199S13.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651446711","title":"Adlai Nortye doses first patient in AN9025 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651446711","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651446711?lang=en_us&edition=fundamental","pubTime":"2026-07-16 19:10","pubTimestamp":1784200225,"startTime":"0","endTime":"0","summary":"Adlai Nortye (ANL) announced that the first patient has been dosed in the United States in the intermittent weekly dosing arm of the ongoing Phase ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adlai-nortye-doses-first-patient-in-an9025-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adlai-nortye-doses-first-patient-in-an9025-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANL","ALN","LU2133065610.SGD","IE00BZ199S13.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651156161","title":"Press Release: Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists","url":"https://stock-news.laohu8.com/highlight/detail?id=2651156161","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651156161?lang=en_us&edition=fundamental","pubTime":"2026-07-13 19:00","pubTimestamp":1783940400,"startTime":"0","endTime":"0","summary":"SINGAPORE and NORTH BRUNSWICK, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (\"Adlai Nortye\" or the \"Company\"), a clinical-stage biotechnology company focused on the developm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1854103824.USD","IDNA","IE00BFMHRM44.USD","BK4099","ALN","BK4512","BK4141","BK4555","LU1548497426.USD","LU0724618433.USD","LU2360107325.USD","LU1983260115.SGD","LU0124384867.USD","03160","IE00BZ199S13.USD","IE00BD6J9T35.USD","BK4604","ANL","ON","BK4605","NETL","LU1720051017.SGD","BK4080","BK4588","GDOC","BK4585","LU1861220033.SGD","LU1720051108.HKD","LU1854104046.USD","LU2133065610.SGD","LU1861219969.SGD","LU0348723411.USD","LU1861215975.USD","LU2357305700.SGD","LU2298322129.HKD","LU1861214812.USD","BK4139","BK4231","ADC","LU1978683503.SGD","TM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645020956","title":"Adlai Nortye Initiated at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2645020956","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645020956?lang=en_us&edition=fundamental","pubTime":"2026-06-22 21:30","pubTimestamp":1782135000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 22, 2026 09:30 ET (13:30 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645269000","title":"Cantor Fitzgerald Initiates Adlai Nortye at Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2645269000","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645269000?lang=en_us&edition=fundamental","pubTime":"2026-06-22 18:36","pubTimestamp":1782124585,"startTime":"0","endTime":"0","summary":"Adlai Nortye (ANL) has an average rating of buy and mean price target of $28.60, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645268110","title":"Adlai Nortye initiated with an Overweight at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2645268110","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645268110?lang=en_us&edition=fundamental","pubTime":"2026-06-22 18:15","pubTimestamp":1782123322,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald initiated coverage of Adlai Nortye (ANL) with an Overweight rating. Published first on TheFly – the ultimate source for real-time...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adlai-nortye-initiated-with-an-overweight-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adlai-nortye-initiated-with-an-overweight-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642249582","title":"Analysts Offer Insights on Healthcare Companies: MetaVia (MTVA) and Adlai Nortye Ltd. Sponsored ADR (ANL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642249582","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642249582?lang=en_us&edition=fundamental","pubTime":"2026-06-09 22:20","pubTimestamp":1781014855,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MetaVia (MTVA) and Adlai Nortye Ltd. Sponsored ADR (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-metavia-mtva-and-adlai-nortye-ltd-sponsored-adr-anl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-metavia-mtva-and-adlai-nortye-ltd-sponsored-adr-anl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IE00BZ199S13.USD","LU0128526141.USD","HCSG","LU2133065610.SGD","BK4139","XBI","BK4137","ALN","BK4581","LABU","BK4588","XLV","ANL","MTVA","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638660577","title":"Adlai Nortye initiated with an Outperform at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2638660577","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638660577?lang=en_us&edition=fundamental","pubTime":"2026-05-28 19:20","pubTimestamp":1779967207,"startTime":"0","endTime":"0","summary":"Oppenheimer initiated coverage of Adlai Nortye (ANL) with an Outperform rating and $32 price target While the shares are up 770% year-to-date on a ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adlai-nortye-initiated-with-an-outperform-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adlai-nortye-initiated-with-an-outperform-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","ALN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638066033","title":"Oppenheimer Initiates Adlai Nortye With Outperform Rating, $32 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2638066033","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638066033?lang=en_us&edition=fundamental","pubTime":"2026-05-28 19:14","pubTimestamp":1779966893,"startTime":"0","endTime":"0","summary":"Oppenheimer Initiates Adlai Nortye With Outperform Rating, $32 Price Target","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPY","ALN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635726484","title":"Adlai Nortye Initiated at Buy by Jones Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2635726484","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635726484?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:42","pubTimestamp":1778791320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 14, 2026 16:42 ET (20:42 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALN","ANL","LU2133065610.SGD","BK4139","IE00BZ199S13.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635744312","title":"Alnylam Steps Into Obesity Drug Race With New ALN-2232 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2635744312","media":"TIPRANKS","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635744312?lang=en_us&edition=fundamental","pubTime":"2026-05-15 00:35","pubTimestamp":1778776557,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals ($ALNY) announced an update on their ongoing clinical study. Alnylam Pharmaceuticals is running a Phase 1/2 trial called “A...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alnylam-steps-into-obesity-drug-race-with-new-aln-2232-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alnylam-steps-into-obesity-drug-race-with-new-aln-2232-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":33,"code":"91000000","status":"200"}]}}